Esophageal cancer (EC) is among the top ten worldwide causes of cancer related morbidity and mortality. Squamous cell carcinoma (SCC) accounts for over 90% of all cases in sub-Saharan Africa [1]. Azygos arch and azygos vein tumor thrombus in esophageal squamous cell carcinoma (ESCC) is a rarely reported phenomenon. We report a case of tumor thrombus in the azygos vein and arch in a patient with esophageal squamous cell carcinoma. To date only a single case of such tumor thrombus in the arch of the azygos vein have been reported which was subsequently managed with neoadjuvant chemotherapy followed by radical resection [2].
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11103353 | PMC |
http://dx.doi.org/10.1016/j.radcr.2024.04.002 | DOI Listing |
Cureus
December 2024
Department of Pediatric Surgery and Vascular Anomalies, Xi'an International Medical Center Hospital, Xi'an, CHN.
Purpose We aimed to report an innovative single-site endoscopic surgery for soft tissue lesions performed at our center. Methods All patients who underwent soft tissue surgery were reviewed. All consecutive patients who underwent single-site endoscopic surgery between September 2019 and March 2024 were included in the study.
View Article and Find Full Text PDFPharmaceuticals (Basel)
December 2024
Department of Rheumatology, Hospital Universitario Infanta Sofía, FIIB HUIS HHEN, Universidad Europea, 28702 Madrid, Spain.
Janus kinase inhibitors (JAKi) have revolutionized the treatment of various inflammatory and immune disorders. Concerns about the potential increased risk of major adverse cardiovascular events (MACEs) associated with JAKi use led to a European Medicines Agency (EMA) health alert recommending restricting the use of JAKi in high-risk populations. This study aims to determine the proportion of patients who developed any cardiovascular, ischemic, neoplastic, or thrombotic adverse event in a cohort of patients receiving, or who have received, JAKi treatment between January 2017 and September 2023.
View Article and Find Full Text PDFJ Clin Med
January 2025
Department of Neurosurgery, University of Luebeck, 23562 Luebeck, Germany.
: This study aims to retrospectively detect associations with postoperative complications in spinal surgeries during the hospitalization period using standardized, single-center data to validate a method for complication detection and discuss the potential future use of generated data. : Data were generated in 2006-2019 from a standardized, weekly complications conference reviewing all neurosurgical operations at the University Hospital Luebeck. Paper-based data were recorded in a standardized manner during the conference and transferred with a time delay of one week into a proprietary complication register.
View Article and Find Full Text PDFCancers (Basel)
January 2025
Department of Urology, Tufts University Medical Center, 800 Washington St., Boston, MA 02111, USA.
Background: Renal cell carcinoma tends to invade venous structures, frequently extending beyond the inferior vena cava and into the heart itself, such as into the right atrium or right ventricle. Resection of tumor burden, particularly tumor thrombus, often requires cardiopulmonary bypass (CPB) and deep hypothermic circulatory arrest (DHCA), which is not feasible for all patients.
Methods: Described in this study is a novel, minimally invasive endovascular approach involving endovascular thrombectomy as a viable approach in these select patients.
Cancers (Basel)
January 2025
Faculty of Medicine and Surgery Via Olgettina, Vita e Salute San Raffaele University, 56, 20132 Milan, Italy.
: Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors with unique biological characteristics and complications, including thromboembolism. This systematic review evaluates the incidence, types, and clinical outcomes of venous thromboembolic events (VTEs) in NEN patients. : A systematic search of PubMed, Scopus, and Embase was conducted to identify studies on TEs in NENs.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!